News
Noticias
Bial creates COVID-19 fund to help community
BIAL has just announced the creation of a fund, with an allocation of 500 thousand Euros, to support several community initiatives in the fight against the coronavirus. "BIAL, as a pharmaceutical company, in addition to ensuring the total maintenance of its activity, which is critical for millions of patients, also intended to make its contribution to the community by creating a fund that we endowed with half a million euros.", said António Portela, CEO of the company. “Unfortunately, we are experiencing a crisis of Public Health worldwide, where the collaboration between all stakeholders - States, governments, universities, companies and society in general - is crucial. With this action, BIAL aims to respond to different needs, some of which have already reached us, from health professionals and institutions, from welfare institutions or within the scope of programs and projects addressed to provide better provision care.”, adds António Portela. Ensuring the supply of medicines in the markets where the company operates is critical for BIAL, which currently does not anticipate constraints in terms of the continuous supply of its medicines. With most employees on home office, people from the Industrial, Quality and Logistics areas continue to work at the company's headquarters, that have extended the production period to reinforce the stocks of their medicines. Having health and safety of its employees and the continuity of the company's operations as priorities, BIAL has defined and has been updating, since the beginning of March, a Contingency Plan focused on the prevention and control of the new coronavirus. Among the measures adopted, BIAL proactively suspended all direct interactions of its employees with Pharmacies, Doctors and other Health Professionals. All visits to the company's headquarters were also cancelled, except for the ones related with the supply of products and materials essential to the maintenance of its activity, as well as the dispatch of medicines. At the same time, a series of measures were reinforced to ensure the safety of employees who remain working, namely in terms of hygiene and social distance. BIAL is constantly monitoring the authorities' guidelines to act accordingly, to update - if necessary - the Contingency Plan that is underway and to ensure that its medicines continue to reach all patients in need.
COVID-19
Aligned with BIAL's position of responsibility, having as a priority the Health of our employees and the continuity of the company's operations in order to ensure the availability of our medicines to all patients, BIAL has been implementing a wide set of measures to prevent and control the spread of the new Coronavirus (COVID-19). BIAL has developed and is implementing a strict Contingency Plan, in accordance with the recommendations of the World Health Organization. We believe that each of us has a role to play in controlling this epidemic. BIAL assumes and will continue to assume a socially responsible position, hoping to actively contribute to the prevention and control of the COVID-19 epidemic and ensure that our medicines remain available to all patients.
BIAL obtain the renewal of the Certificates of its Management Systems of Quality, Environment and Occupational Health and Safety
Certificates of Management Systems of Quality, Environment and Occupational Health and Safety, implemented in accordance with ISO 9001 / ISO 14001 / OSHAS 18001 standards, respectively These renovations reflect the consistency of BIAL’s Management Systems and the importance that each of these areas assume: Quality, as a strategic pillar of the company, the promotion of a healthy and safe work environment for all employees and environmental protection, translated into the recent signing of the “Business Ambition for 1.5ºC” agreement, an initiative of the United Nations Global Compact, to which BIAL has been a signatory since 2004.
BIAL Italy granted ISO 9001 certification, an entitlement on Quality Management Systems
BIAL Italy S.R.L has just been successfully granted the ISO 9001:2015 certification, by Certiquality/ IQNET. ISO 9001 takes over a process-based approach, which incorporates the PDCA (Plan-Do-Check-Act) cycle of continuous improvement, and integrates risk-based thinking. With this achievement BIAL Italy demonstrates its trustfulness and quality, with the ability to consistently provide products and services that meet customer, partners and regulatory requirements, using a global recognized standard. In Portugal, BIAL is certified by APCER/ IQNET since 1998. Certificato IQnet BIAL Italia S.R.L.: 9001 - 2015
The American Heart Association distinguished the work of BIAL’s R&D team
Four researchers from BIAL’s Research and Development (R&D) area were recognized as a "2019 Paul Dudley White International Scholar" by the American Heart Association. At the American Heart Association Scientific Sessions 2019, an event held in Philadelphia. The award aims to recognize authors that contributed to the highest ranked accepted abstract from each country.
BIAL responds to the call and signs “Business Ambition for 1.5ºC” agreement
Signed by several business leaders, this initiative empowers companies worldwide, and BIAL has made the commitment. The initiative of the United Nations Global Compact, to which BIAL has been a signatory since 2004, establishes specific targets and emission reduction goals, in order to reach the net-zero emissions by 2050 and restrict the global warming in 1.5ºC by 2030. “The document encourages organizations to truly commit themselves to the preservation of the planet by requiring them to commit to concrete measures to reduce greenhouse gas emissions, critical to stop global warming. Achieving the transition to a low carbon economy and avoiding the atmosphere’s overheating are its main goals”, according to the Global Compact Network Portugal’s statement. Find out more at https://unglobalcompact.org/take-action/events/climate-action-summit-2019/business-ambition.
BIAL takes part of a recruitment event promoted by “Associação Salvador" - Porto, Portugal
The “Associação Salvador”, which promotes the inclusion of people with motor disabilities, organized this initiative which aimed to train and the job search for 40 candidates, in Porto BIAL joined this initiative promoted by Associação Salvador, which included a speed recruitment gathered 18 companies and several applicants, totaling over 210 interviews. At BIAL, we stand up for a more inclusive recruitment, insuring non-discrimination practices based on any personal characteristics, including social status, ethnicity, gender, age, religion, sexual orientation, marital status, political opinion, disability or incapacity. Learn more about our Code of Ethics and Conduct.
BIAL Foundation marks its 25th anniversary with an itinerant exhibition
To mark this occasion, the Foundation organizes the itinerant exhibition BIAL Foundation - 25 Years, which discloses the work developed on the study and scientific research of the human being during the last two decades.
BIAL has two new board members
José Almeida Bastos and Richard Pilnik integrate the Board of Directors of the biggest pharmaceutical company in Portugal José Almeida Bastos is now part of BIAL’s Executive Committee and responsible for both national and international commercial operations. Richard Pilnik has a 35 year career in the health sector, and is now non-executive member of BIAL’s Board of Directors. According to António Portela, CEO of BIAL, “it is an honor to have José Almeida Bastos and Richard Pilnik onboard. With their wide experience, they will endow the company with a more prepared structure to deal with upcoming challenges within the strategic lines we have defined, the research and development of new medicines, consolidated in an international scale. The Board of Directors of BIAL consists of 8 members: Luís Portela (Chairman), António Portela (CEO), Richard Pilnik (Non-Executive), Isabel Morgado, José Redondo, Miguel Portela, Patrício Soares da Silva and José Almeida Bastos.